Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application

Lehmann, Sylvain ; Hoofnagle, Andrew ; Hochstrasser, Denis ; Brede, Cato ; Glueckmann, Matthias ; Cocho, José A. ; Ceglarek, Uta ; Lenz, Christof ; Vialaret, Jérôme ; Scherl, Alexander ; Hirtz, Christophe

In: Clinical Chemistry and Laboratory Medicine, 2013, vol. 51, no. 5, p. 919-935

Add to personal list
    Summary
    Proteomics studies typically aim to exhaustively detect peptides/proteins in a given biological sample. Over the past decade, the number of publications using proteomics methodologies has exploded. This was made possible due to the availability of high-quality genomic data and many technological advances in the fields of microfluidics and mass spectrometry. Proteomics in biomedical research was initially used in ‘functional' studies for the identification of proteins involved in pathophysiological processes, complexes and networks. Improved sensitivity of instrumentation facilitated the analysis of even more complex sample types, including human biological fluids. It is at that point the field of clinical proteomics was born, and its fundamental aim was the discovery and (ideally) validation of biomarkers for the diagnosis, prognosis, or therapeutic monitoring of disease. Eventually, it was recognized that the technologies used in clinical proteomics studies [particularly liquid chromatography-tandem mass spectrometry (LC-MS/MS)] could represent an alternative to classical immunochemical assays. Prior to deploying MS in the measurement of peptides/proteins in the clinical laboratory, it seems likely that traditional proteomics workflows and data management systems will need to adapt to the clinical environment and meet in vitro diagnostic (IVD) regulatory constraints. This defines a new field, as reviewed in this article, that we have termed quantitative Clinical Chemistry Proteomics (qCCP)